Future and alternative approaches to managing Clostridium difficile infection-Reference-Cited by-同舟云学术

Future and alternative approaches to managing Clostridium difficile infection

Published:2013-08 Issue: Volume: Page:126-139
ISSN:
Container-title:Clostridium difficile: New Challenges for an Old Foe
language:
Short-container-title:

Author:

Tillotson Glenn S¹,Weiss Karl²

Affiliation:

1. Glenn S Tillotson has almost 30 years of pharmaceutical experience, including clinical research, commercialization, medical affairs, strategic drug development, life-cycle management and global launch programs. While at Bayer (Leverkusen, Germany), he was instrumental in the development of ciprofloxacin and moxifloxacin. He has held various medical affairs leadership roles in the past decade. He has published over 140 peer-reviewed manuscripts and is on several journal editorial advisory boards.

2. Karl Weiss is Chief of the Department of Infectious Diseases and Medical Microbiology at Maisonneuve-Rosemont Hospital in Montreal (QC, Canada). He is also Professor of Medicine at the Faculty of Medicine at the University of Montreal (QC, Canada), Director of Pharmacological Research at Maisonneuve-Rosemont Hospital and Co-Chair of the Montreal Infection Control Board. He is also an associate member of the Division of Infectious Diseases at the Jewish General Hospital in Montreal (QC, Canada), and...

Publisher

Future Medicine Ltd

Link

https://www.futuremedicine.com/doi/pdf/10.2217/ebo.13.308

Reference28 articles.

1. Patino H , Stevens C , Louie T et al. Efficacy and safety of the lipopetide CB183,315 for the treatment of Clostridum difficile infection. Presented at: the Interscience Conference on Antimicrobial Agents. IL, USA, 17–20 September 2011 .

2. Cannon K , Byrne B , Happe J , Louie T . Enteric microbiome profiles during a Phase 2 clinical trial of CB 183.315 or vancomycin for the treatment of Clostridium difficile infection. Presented at: the 22nd European Congress of Clinical Microbiology and Infectious Diseases. London, UK, 31 March–3 April 2003 .

3. Louie T , Buitrago M , Cornely O et al. Multicentre, double blind, randomised, Phase 2 study evaluating the novel antibiotic, cadazolid, in subjects with Clostridium difficile-associated diarrhea. Presented at: the 23rd European Congress of Clinical Microbiology and Infectious Diseases. Berlin, Germany, 27–30 April 2013 .

4. Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications

5. McKenney D , Williams A , LaManche M et al. Efficacy comparison between LFF571 and fidaxomicin in the hamster model of C. difficile infection. Presented at: the 52nd Interscience Conference on Antimicrobial Agents. San Francisco, CA, USA, September 9–12 (2012) .